Evgeny Yurievich Garbukov

Evgeny Yurievich Garbukov

Auto-generated profile, based on publicly available information

Evgeny Yurievich Garbukov

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VPVladimir M. Perelmuter
Vladimir M. Perelmuter
EGEvgeniya Grigoryeva
Evgeniya Grigoryeva
VAVladimir Valerievich Alifanov
Vladimir Valerievich Alifanov
AKAnna Kalinchuk
Anna Kalinchuk
EAElena S. Andryuhova
Elena S. Andryuhova
LTLiubov Tashireva
Liubov Tashireva
Most studies on CTCs have focused on isolating cells that express EpCAM. In this study, we emphasize the presence of EpCAM-negative and EpCAMlow CTCs, in addition to EpCAMhigh CTCs, in early BC. We evaluated stem cell markers (CD44/CD24 and CD133) and EMT markers (N-cadherin) in each subpopulation. Our findings indicate that all stemness variants were present in both EpCAMhigh and EpCAM-negative CTCs, whereas only one variant of stemness (nonCD44+CD24−/CD133+) was observed among EpCAMlow CTCs. Nearly all EpCAMhigh CTCs were represented by CD133+ stem cells. Notably, the hybrid EMT phenotype was more prevalent among EpCAM-negative CTCs. scRNA-seq of isolated CTCs and primary tumor partially confirmed this pattern. Therefore, further investigation is imperative to elucidate the prognostic significance of EpCAM-negative and EpCAMlow CTCs.

12 April 2021 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
OBOlga Bragina
Olga Bragina
VCVladimir Chernov
Vladimir Chernov
EGE. Yu. Garbukov
E. Yu. Garbukov
ADA. V. Doroshenko
A. V. Doroshenko
AVAnzhelika Vorobyeva
Anzhelika Vorobyeva
Vladimir TolmachevVladimir Tolmachev
Vladimir Tolmachev
Возможности радионуклидной диагностики Her2-позитивного рака молочной железы с использованием меченных технецием-99m таргетных молекул: первый опыт клинического применения

27 November 2022 in Drug development & registration
Verified
Journal Article
Open access
PDF file
AMAnna Medvedeva
Anna Medvedeva
VCVladimir Chernov
Vladimir Chernov
RZRoman Zelchan
Roman Zelchan
OBOlga Bragina
Olga Bragina
ARAnastasia Rybina
Anastasia Rybina
EGE. Yu. Garbukov
E. Yu. Garbukov
Introduction. In modern oncology, the identification of sentinel lymph nodes (SLN), the first nodes that stand on the way of malignant tumor metastasis, is of increasing interest. Detection of SLN followed by morphological examination allows personalizing the surgical intervention for early breast cancer, melanoma, head and neck tumors, neoplasms of the cervix and endometrium. Currently, there is an active development of specific radiopharmaceuticals for SLN imaging. Within the framework of the grant from the Federal Target Program "Pharma-2020", an original radiopharmaceutical using gamma aluminum oxide – [99mТс]-Al2O3 was developed. Preclinical studies have been demonstrated its effectiveness and safety. Pharmacokinetic studies of [99mTc]-Al2O3 showed that 24 hours after its subcutaneous administration, about 12 % of the administered dose is accumulated in the SLN, which gives possibility for its detection.Aim. To study the possibility of clinical [99mTc]-Al2O3 using for visualization of SLN in breast, larynx and laryngopharyngeal cancer.Materials and methods. The definition of SLN was carried out in 55 patients with breast cancer and 30 patients with malignant tumors of the larynx and laryngopharynx. The study included peritumoral radiopharmaceutical injection, single-photon emission computed tomography with qualitative and quantitative analysis of the images and radioguided surgery detection of lymph nodes with their subsequent morphological examination.Results and discussion. Clinical studies have shown that radionuclide imaging of SLN using [99mTc]-Al2O3 is characterized by high sensitivity in breast cancer, larynx and laryngopharyngeal cancer patients (94.5 and 90 %, respectively), due to the high-intensity accumulation of this radiopharmaceutical in the lymph nodes. The optimal time point for SPECT and radioguided examination is an interval of 18–20 hours after injection of [99mTc]-Al2O3, which allows visualizing the maximum possible number of lymph nodes with the most optimal level of radioactivity for their detection.Conclusion. Application of radionuclide imaging of SLN with the use of [99mTc]-Al2O3 as a radiopharmaceutical is useful in planning surgical treatment of patients with tumors of the breast, larynx and laryngopharynx to determine the extent of surgery.

1 January 2021 in Молекулярная медицина
Verified
Journal Article
Closed access
OBOlga Dmitrievna Bragina
Olga Dmitrievna Bragina
VCVladimir Chernov
Vladimir Chernov
MLMariia Sergeevna Larkina
Mariia Sergeevna Larkina
ESElene Sergeevna Stasyuk
Elene Sergeevna Stasyuk
RZRoman Zelchan
Roman Zelchan
Vladimir TolmachevVladimir Tolmachev
Vladimir Tolmachev

27 October 2022 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
MTMatvey M. Tsyganov
Matvey M. Tsyganov
MIMarina Ibragimova
Marina Ibragimova
EGE. Yu. Garbukov
E. Yu. Garbukov
OBOlga Bragina
Olga Bragina
EZE. A. Zdereva
E. A. Zdereva
NLNikolai Litviakov
Nikolai Litviakov
ABC-transporter family genes have been well studied and their involvement in the development of drug resistance has been assessed. The presence of aberrant conditions in these genes can affect the treatment and prognosis of the disease. Loss of heterozygosity (LOH) is one of these conditions; it is a common event in cancer development. therefore, The aim of this study was to investigate the relationship between LOH in ABC transporter genes in breast cancer and response to chemotherapy and disease prognosis. Material and methods. a total of 130 breast cancer patients were included in the study. microarray analysis was performed on Affymetrix Cytoscantm HD Array high-density DNA chips to assess LOH status. Chromosome Analysis Suite 4.1 software (Affymetrix, USA) was used to process microarray results. Results. Forty-nine ABC transporter genes were evaluated for LOH. the frequency of LOH ranged from 6.9 % to 90 %. an association analysis identified two genes: ABCG5 and ABCG8, in which the presence of LOH was associated with a lack of objective response to neoadjuvant chemotherapy. the presence of LOH in the ABCA5, ABCA6, ABCA8, ABCA9, ABCA10 and ABCC3 genes was associated with high rates of metastasis-free survival (log-rank test, p<0.04). Conclusion. The presence of loss of heterozygosity in the ABC transporter genes was found to have no significant effect on the response to chemotherapy. However, a high prognostic potential of ABCA family genes was found.

27 May 2026 in Acta Biomedica Scientifica
Verified
Journal Article
Closed access
MIMarina Ibragimova
Marina Ibragimova
EKEkaterina Kravtsova
Ekaterina Kravtsova
MTMatvey M. Tsyganov
Matvey M. Tsyganov
ASA. K. Shagabudinova
A. K. Shagabudinova
KGKsenia Andreevna Gaptulbarova
Ksenia Andreevna Gaptulbarova
NLNikolai Litviakov
Nikolai Litviakov
Background . Neoadjuvant chemotherapy (NAC) is a common treatment option for patients with triple-negative and HER2-positive breast cancer (BC) subtypes. The use of NAC in HER2-negative breast cancer is a matter of debate. For patients with HR+/HER2-breast cancer, the choice of NAC is still based on clinical and pathological characteristics rather than on biomarkers with a certain clinical value, in contrast to adjuvant therapy, where gene expression signatures are widely used for decision-making. Therefore, it is imperative to evaluate not only the efficacy of NAC but also to identify markers for disease prognosis in this specific patient group. Aims . In this work, we studied the changes in the expression profile of HER2-negative breast tumors when using taxane-containing NAC regimens. Material and methods . The material used was paired biopsy samples before treatment and tumor tissue (after NAC) for each patient. The expression landscape of the tumor was assessed using whole transcriptome microarray analysis using Clariom™ S Assay, human microarrays (Affymetrix, USA). Overall and metastasis-free survival curves for patients included in the study were constructed using the Kaplan-Meier method. The obtained result was validated on an independent sample. Results . As a result, a comparison of the expression profile of the tumor of patients before and after NAC with taxane-containing regimens determined that the expression level of the PODXL2 gene in the tumor before treatment, depending on the response to therapy, and the level of expression of the NR2E1 and TMEM98 genes in the tumor after NAC, depending on the status of hematogenous metastasis, statistically significantly correlate with the OS and RFS of patients, respectively. Conclusions . Potential expression markers of an objective response to the applied treatment and prediction of the occurrence of hematogenous metastasis of HER2-negative breast tumors were identified when prescribing taxane-containing treatment regimens.